SCHEMBL150762

SCHEMBL150762

c1ccc(-c2cnnnn2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 3/20 0.48
GABRG2 P18507 3/20 0.48
GABRB3 P28472 3/20 0.48
GABRA5 P31644 3/20 0.48
GABRA3 P34903 3/20 0.48
RAB9A P51151 5/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
AKT1 P31749 1/20 0.41
AKT2 P31751 1/20 0.41
NPC1 O15118 5/20 0.41
ALDH1A1 P00352 4/20 0.41
IDO1 P14902 1/20 0.40
METAP2 P50579 1/20 0.40
KEAP1 Q14145 1/20 0.40
MAPK1 P28482 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.38
SMARCA2 P51531 1/20 0.38
SMARCA4 P51532 1/20 0.38
PBRM1 Q86U86 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29429231 1.00 GABRA1 (0.48) GABRA1GABRG2GABRB3GABRA5GABRA3
Bromide SCHEMBL28568919 0.98 GABRA1 (0.47) GABRA1GABRG2GABRB3GABRA5GABRA3
Benzamide SCHEMBL28855712 0.82 CYP2C19 (0.52) RAB9ANPC1ALDH1A1SMN1; SMN2HPGD
SCHEMBL30950412 0.76
SCHEMBL29584431 0.76 GABRG2 (0.51) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL12806833 0.72 GABRA1 (0.54) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL151034 0.71 GABRA1 (0.43) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL21938127 0.71 GABRA1 (0.54) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL29516145 0.71 GABRA1 (0.43) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL23888753 0.71 KDM4E (0.58) RAB9ANPC1ALDH1A1METAP2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4731603-A1 LOW TEMPERATURE REACTIVE ARYL AZIDES SuSoS AG (CH) 2026-04-29 EP claimed
WO-2024261308-A1 LOW TEMPERATURE REACTIVE ARYL AZIDES SUSOS AG (CH) 2024-12-26 WO claimed
US-20190189933-A1 ORGANIC SEMICONDUCTOR MATERIAL FOR ELECTRON TRANSPORT DAEGU GYEONGBUK INSTITUTE OF SCIENCE & TECHNOLOGY (KR) 2019-06-20 US claimed
EP-4731603-A1 LOW TEMPERATURE REACTIVE ARYL AZIDES SuSoS AG (CH) 2026-04-29 EP disclosed
US-20260021196-A1 HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING SYNAFFIX BV (NL) 2026-01-22 US disclosed
EP-4658318-A1 HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING Synaffix B.V. (NL) 2025-12-10 EP disclosed
WO-2024261308-A1 LOW TEMPERATURE REACTIVE ARYL AZIDES SUSOS AG (CH) 2024-12-26 WO disclosed
CN-118955522-A Naphthalene radical hybridization molecular tube and preparation method and application thereof 南方科技大学 2024-11-15 CN disclosed
WO-2024187006-A1 BIOORTHOGONAL ACTIVATION OF PROTAC PRODRUGS ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2024-09-12 WO disclosed
WO-2024160926-A1 HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING SYNAFFIX B.V. (NL) 2024-08-08 WO disclosed
EP-4410313-A1 HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING Synaffix B.V. (NL) 2024-08-07 EP disclosed
US-9293768-B2 Battery electrode, method of producing the same, nonaqueous electrolyte battery, battery pack, and active material KABUSHIKI KAISHA TOSHIBA (JP) 2016-03-22 US disclosed
EP-2986603-A1 RADIOLABELED GNRH ANTAGONISTS AS PET IMAGING AGENTS Oslo Universitetssykehus HF (NO) 2016-02-24 EP disclosed
US-20150279654-A1 TREATING SOLUTION FOR ELECTRONIC PARTS, AND PROCESS FOR PRODUCING ELECTRONIC PARTS FINE POLYMERS CORPORATION (JP) 2015-10-01 US disclosed
US-20150279654-A1 TREATING SOLUTION FOR ELECTRONIC PARTS, AND PROCESS FOR PRODUCING ELECTRONIC PARTS FINE POLYMERS CORPORATION (JP) 2015-10-01 US disclosed
US-20150279654-A1 TREATING SOLUTION FOR ELECTRONIC PARTS, AND PROCESS FOR PRODUCING ELECTRONIC PARTS FINE POLYMERS CORPORATION (JP) 2015-10-01 US disclosed
WO-2014184682-A9 RADIOLABELED GNRH ANTAGONISTS AS PET IMAGING AGENTS OSLO UNIVERSITETSSYKEHUS HF (NO) 2015-01-29 WO disclosed
WO-2014184682-A1 RADIOLABELED GNRH ANTAGONISTS AS PET IMAGING AGENTS OSLO UNIVERSITETSSYKEHUS HF (NO) 2014-11-20 WO disclosed
US-20120058395-A1 BATTERY ELECTRODE, METHOD OF PRODUCING THE SAME, NONAQUEOUS ELECTROLYTE BATTERY, BATTERY PACK, AND ACTIVE MATERIAL KABUSHIKI KAISHA TOSHIBA (JP) 2012-03-08 US disclosed
US-3863010-A Compositions of matter and method of use of phenyl and substituted phenyl tetrazines AMERICAN CYANAMID CO 1975-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260021196-A1 HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING FCGR2A, FCGR3B, FCGR1A GABRA1 600/4885GABRG2 1063/4885GABRB3 1396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.